Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Investors Ponder Likely Effects Of Radical Policies Donald Trump’s victory in the US presidential election has deep significance for the inv ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...